Medication & Safety
Return and Refund Policy: What to Check Before You Buy
A clear return and refund policy tells you a lot about a seller before anything goes wrong. Here is what to check before...
Semaglutide has begun coming off patent, and the price effects in some markets have been dramatic. This is the most significant development in weight loss medication economics in a decade.
It is also widely misunderstood, and what it means for Pakistan is more complicated than the headlines suggest.
What is happening
Semaglutide patents began expiring from April 2026 across a group of markets including India, China, Canada, Brazil, Turkey, Mexico, Saudi Arabia and South Africa.
Patent expiry allows other manufacturers to produce the same molecule legally. Historically that produces steep price falls, because competition replaces monopoly pricing.
In India, more than 40 pharmaceutical companies have been preparing to launch semaglutide versions. Reported Indian pricing has fallen sharply, from figures in the range of ₹10,000 to ₹16,000 per month for branded product to as little as around ₹1,290 per month for the cheapest generics.
Those figures are Indian rupees, not Pakistani rupees. The distinction matters and is frequently blurred in coverage that circulates here.
Separately, generic liraglutide has already arrived in the United States. The FDA approved generic liraglutide injection, and a generic version of Saxenda was approved and launched, making it the first generic GLP-1 product specifically indicated for weight loss.
Why prices fall so far
Two forces operate together.
Competition. A single manufacturer sets price against what the market will bear. Twenty manufacturers set price against each other.
Regulatory mechanisms. Some markets mandate reductions. In Canada, once three generics of an injectable are on the market, the price must legally fall to 35 percent of the brand price, a 65 percent cut.
The result in India has been a collapse rather than a decline.
What this does not mean for Pakistan
Here is where careful reading matters, because the optimistic reading is wrong.
Pakistan is not on the patent expiry list. The markets named above do not include Pakistan.
Semaglutide has never been registered in Pakistan anyway. Patent expiry elsewhere does not create a registration here. A drug being cheap in India does not make it legally available in Karachi.
Cheaper elsewhere does not mean obtainable here. Everything reaching Pakistan still arrives through personal import, informal medical supply or resale. Those channels remain unregulated regardless of what the product costs at origin.
Indian rupee prices are not Pakistani rupee prices. Currency conversion, transport, intermediary margins and scarcity pricing all apply between an Indian pharmacy shelf and a Pakistani buyer.
What it probably does mean
Being realistic rather than dismissive, several effects are likely.
Informal import pressure will increase. A large, low-cost supply immediately across the border changes the economics of unofficial channels substantially. Expect more product offered, at lower prices than imports from Western markets.
Price expectations will shift. Buyers who read about ₹1,290 in India will not accept Rs 40,000 quotes without question, which is healthy.
Counterfeit risk will rise, not fall. This is the part most coverage misses. A flood of cheap product from many manufacturers, moving through unregulated channels, is an easier environment to insert counterfeits into, not a harder one. The World Health Organization estimates at least 1 in 10 medical products in low- and middle-income countries is substandard or falsified, and notes these are often sold online or informally.
Eventual registration becomes more plausible. Cheaper inputs make local registration commercially viable in a way branded pricing never did. That is a genuine medium-term possibility, though not a current one.
Generic does not mean inferior
Worth addressing, because the assumption is common.
A properly manufactured generic contains the same active molecule and must demonstrate bioequivalence to be approved. In regulated markets, generic semaglutide from a licensed manufacturer is the same drug.
The efficacy data still applies. STEP 1, published in the New England Journal of Medicine, found semaglutide 2.4 mg produced an average 14.9 percent body weight reduction over 68 weeks. That describes the molecule, not the brand.
The caveat is regulatory oversight, not the generic concept. A generic approved by a competent regulator, made at a licensed facility, is reliable. A product described as generic semaglutide, sold informally, with no registration and no verifiable manufacturer, is not the same thing at all.
The word generic on an unregulated product is a marketing term, not a quality assurance.
What to be careful about
"Generic semaglutide" as a sales pitch. Expect a surge of sellers using the term. Ask which manufacturer, approved by which regulator, and how it reached Pakistan.
Cold chain across a longer chain. Cheap product moving through more hands, over longer routes, with thinner margins, is less likely to be properly refrigerated throughout.
Compounded or mixed products presented as generics. These are different things.
Price as reassurance. In this specific situation, cheap no longer automatically signals fake, which removes one of the few heuristics buyers had. That makes the other checks more important, not less.
What is registered here now
The honest position is that this development is genuinely good news for global access to weight loss medication, and it does not currently change what is legally available in Pakistan.
Until semaglutide is registered here, obtained through a licensed local supply chain, with verifiable manufacturing and a prescribing pathway, it remains an unregistered import whatever it costs.
For what's actually available in Pakistan today, METASLIM™ is a physician-reviewed sublingual supplement working on the GLP-1 appetite pathway, with physician review before dispatch. It is not semaglutide, generic or branded, and does not produce STEP 1 results. Anyone suggesting otherwise is misleading you.
What it offers is consistent, physician-reviewed manufacturing, which is precisely what an informally imported generic cannot guarantee regardless of price.
Our guide to counterfeit weight loss products explains how to check a seller's claims, and why GLP-1 prices rise and supply breaks covers the market dynamics. You can compare weight loss treatments available in Pakistan in one place.
The summary
Semaglutide patents began expiring from April 2026 in India, China, Canada, Brazil, Turkey, Mexico, Saudi Arabia and South Africa.
More than 40 Indian companies have been preparing generics, and Indian prices have fallen from roughly ₹10,000 to ₹16,000 monthly to as little as around ₹1,290 for the cheapest.
Generic liraglutide has already launched in the United States, including a generic Saxenda for weight loss.
Pakistan is not on the expiry list, and semaglutide has never been registered here.
Cheap product moving through unregulated channels raises counterfeit risk rather than reducing it.
See the current program price for a physician-reviewed option available here now.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.